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Superantigens produced by Streptococcus pyogenes
have been implicated with streptococcal toxic shock syn-
drome (STSS). We analyzed 19 acute-phase serum sam-
ples for mitogenic activity from patients with severe strepto-
coccal disease. The serum samples from two patients in
the acute phase of STSS showed strong proliferative activ-
ity. Streptococcal mitogenic exotoxin (SME) Z-1 and strep-
tococcal pyrogenic exotoxin (SPE)-J were identified in one
patient with peritonitis who recovered after 2 weeks in
intensive care. SMEZ-16 was found in a second patient
who died on the day of admission. Sequential serum sam-
ples taken on day 3 after admission from patient 1 showed
clearance of mitogenic activity but absence of neutralizing
anti-SMEZ antibodies. Serum samples taken on day 9 from
this patient showed evidence of seroconversion with high
levels of anti-SMEZ antibodies that neutralized SMEZ-1
and 12 other SMEZ-variants. These results imply that a
high level of SMEZ production by group A streptococcus is
a causative event in the onset and subsequent severity of
STSS. 
S
ince the 1980s, a marked increase has occurred in high-
ly invasive group A streptococcal (GAS) infections, in
particular streptococcal toxic shock syndrome (STSS)
associated with necrotizing fasciitis or myositis (1–4). The
classical case definition for STSS is similar to staphylo-
coccal toxic shock, caused by Staphylococcus aureus, but
the outcome is more serious in STSS, with a reported death
rate of 30% to 70% (2,5,6).
The multiorgan involvement in STSS suggests that a
toxin produced by GAS might be involved in pathogene-
sis. Prime candidates are the streptococcal superantigens
(SAgs), a family of highly mitogenic proteins secreted
individually or in certain combinations by many
Streptococcus pyogenes strains (7–10), although other vir-
ulence factors, such as streptolysin O and various cell wall
antigens can also cause toxic shock (11). Superantigens
simultaneously bind to major histocompatibility complex
class II molecules and T-cell receptor molecules bearing a
particular V-β region. This binding results in the activation
of a large proportion of antigen-presenting cells and T
cells, with subsequent release of high systemic levels of
cytokines (12–15). 
Several lines of evidence support the hypothesis of SAg
involvement in STSS. Toxic shock syndrome (TSS) toxin,
produced by S. aureus, has been associated with most
menstrual TSS cases (7). TSS toxin is a typical SAg that is
functionally and structurally related to the staphylococcal
and streptococcal SAgs (16). Moreover, animal models
have shown that TSS toxin and other SAgs induce TSS-
like symptoms in rabbits and rodents (17,18). The lack of
neutralizing anti-SAg antibodies appears to be a key risk
factor for the development of staphylococcal and strepto-
coccal toxic shock (19,20).
The major cytokines released from antigen-presenting
cells and T cells after activation by SAgs are tumor necro-
sis factor alpha (TNF-α), tumor necrosis factor beta (TNF-
β), interleukin (IL)-1, and IL-2 (11–14). TNF-α is the
prime mediator of shock; anti–TNF-α has been shown to
inhibit the progression of SAg-driven shock in mice and
baboons (17,18,21).
In contrast to TSS toxin and staphylococcal TSS, the
association of individual streptococcal SAgs to STSS is
much less understood. Several studies described the poten-
tial involvement of streptococcal pyrogenic exotoxin
(SPE) A in invasive streptococcal disease (2,19,22,23),
while others reported an association with SPE-C (24,25).
In addition, some cases of STSS are not associated with
SPE-A or SPE-C (26). Notably, these studies were per-
formed without knowledge of other streptococcal SAgs
that are now known to exist.
Superantigen activity found in acute-phase serum sam-
ples from streptococcal disease patients has been reported.
(In this article, the term “acute-phase serum” refers to
serum taken on the day of admission). Sriskandan et al.
published a study of seven patients with severe streptococ-
cal infections: SPE-Awas detected in serum samples from
four patients (27). Recently, Norby-Teglund and Berdal
reported a strong proliferative response in an acute-phase
serum sample collected from a patient with STSS, indicat-
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Mitogenic activity was also detected in serum samples
from mice infected with a SAg-producing S. pyogenes
strain (29).
Since these reports, several novel streptococcal SAgs
have been identified, including streptococcal mitogenic
exotoxin Z (SMEZ; 30), SMEZ-2, SPE-G, SPE-H (31),
SPE-J, and SPE-I (32), all possessing typical SAg features
and are highly mitogenic on human T cells. In addition,
several variants of SMEZ showed significant antigenic
variation (33). These findings suggest that, in addition to
SPE-A and SPE-C, one or more of these novel toxins
might be involved in STSS.
All known streptococcal SAgs (with the exception of
SMEZ, SPE-G, and SPE-J) are localized on mobile DNA
elements (34). As a consequence, each GAS isolate usual-
ly carries the genes for SMEZ, SPE-G, and SPE-J, plus a
certain combination of other sag genes. Not much is
known about the control of sag gene expression, but a
recent study indicates that an unknown host factor is
involved in the control of SPE-C expression (35)
We analyzed serum samples from 19 patients with
severe streptococcal infections for mitogenic activity to
identify bioactive SAgs and find a correlation between
SAg activity and disease severity. In addition, we geno-
typed the matching streptococcal isolates from these
patients for all known streptococcal sag genes and tested
them for their ability to produce SAg protein in vitro. 
Material and Methods
Patient Serum Samples and Streptococcal Isolates
We included serum samples from all 21 patients
referred to the Hammersmith Hospital’s Infectious
Diseases service from November 1994 to November 2000
who had microbiologically confirmed invasive GAS dis-
ease and required hospital admission. Two patients who
used intravenous drugs were subsequently excluded to
reduce the risk for bloodborne viruses. Aliquots of serum
(residual to serum required for clinical purposes) were sep-
arated from blood drawn for clinical purposes and frozen
immediately at –70°C before testing for mitogens or anti-
bodies. Samples were obtained at the point of admission to
hospital (at initiation of antibiotic therapy) and then on
sequential days during treatment up to a maximum of 10
days. Streptococcal isolates were cultured directly from
blood or tissue, identified by the hospital diagnostic labo-
ratory, and then cultured once in Todd Hewitt broth before
immediate freezing in 15% glycerol and before growth for
SAg analysis. All 19 patients had invasive streptococcal
disease; patients with STSS were identified by using stan-
dard criteria (1–3) (Table). The study was approved by the
Hammersmith Hospital Research Ethics Committee.
Toxin Proliferation Assay
Human peripheral blood lymphocytes (PBLs) were
purified from blood of a healthy donor by using
Histopaque Ficoll (Sigma Chemical Co., St. Louis, MO)
fractionation. PBLs were incubated in 96-well, round-bot-
tom microtiter plates at 105 cells per well with RPMI-10
(RPMI with 10% fetal calf serum [FCS]) containing vary-
ing dilutions of recombinant toxins. After 3 days, 0.1 µCi
[3H] thymidine was added to each well and cells were
incubated for another 24 h. Cells were harvested and
counted on a scintillation counter.
Jurkat cells (a human T-cell line) and LG-2 cells (a
human B-lymphoblastoid cell line, homozygous for HLA-
DR1) were harvested in log phase and resuspended in
RPMI-10. One hundred microliters of the cell suspension,
containing 1x105 Jurkat cells and 2x104 LG-2 cells was
mixed with 100 µL of  S. pyogenes culture supernatant
(undiluted, 1:10, 1:100) on 96-well plates. After incubating
overnight at 37°C, 100-µL aliquots were transferred onto a
fresh plate and 100 µL (1x104) of SeI cells (IL-2 depend-
ent murine T-cell line) per well was added. After incubat-
ing for 24 h, 0.1 µCi [3H] thymidine was added to each
well, and cells were incubated for another 24 h. Cells were
harvested and counted on a scintillation counter. As a con-
trol, a dilution series of IL-2 was incubated with SeI cells. 
PBLs were obtained and stimulated as described under
toxin proliferation assay above, with the exception that the
10% FCS was replaced by 5% FCS plus 5% patient serum.
All recombinant toxins were used at subsaturating concen-
trations, which were 0.05 ng/mL(SMEZ-2), 0.1 ng/mL(all
other SMEZ variants, SPE-C, SPE-I, SPE-J, streptococcal
superantigen [SSA]), 1 ng/mL(SPE-G), 2 ng/mL(SPE-A),
and 10 ng/mL (SPE-H).
PBLs from a single donor were used for all tests. We
determined the neutralizing response by comparing the T-
cell proliferation with a control test using 10% FCS instead
of 5% patient serum plus 5% FCS. The relative inhibition
was calculated as 1-[cpm (patient serum) per cpm
(FCS)]x100.
S. pyogenes isolates were grown overnight in 10 mL of
brain heart infusion (BHI) medium (Difco Laboratories,
Detroit, MI) at 37°C in 15-mL Falcon tubes without agita-
tion. The cells were spun down and washed, and the
genomic DNA was extracted as described previously (33).
The purified DNAwas resuspended in 50 µLof Tris-EDTA
buffer and used for polymerase chain reaction (PCR) with
specific primers for the speA, speC, speG, speH, speI, speJ,
ssa, and smez genes as described previously (31–33). In
addition, a primer pair specific to a DNA region encoding
the 23S rRNA (33) was used as a positive control.
Recombinant forms of SPE-A, SPE-C, SPE-G, SPE-H,
SPE-I, SPE-J, SSA, SMEZ-1, and SMEZ-2 were produced
in Escherichia coli by using the pGEX-2T expression sys-
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rabbits were immunized with 50 µg of recombinant protein
in 1-mL phosphate-buffered saline and 1-mL incomplete
Freund’s adjuvants (Invitrogene, San Diego, CA) followed
by a booster injection 4 weeks later. The rabbits were bled
10 days after the booster injection. SMEZ-1 and SMEZ-2
were injected as a 1:1 mixture to ensure generation of anti-
bodies against a large panel of the SMEZ variants.
Western Blot Analysis
S. pyogenes isolates were grown overnight in modified
BHI medium at 37°C. The medium was prepared by dia-
lyzing 100-mL of 10X concentrated BHI medium against
1 Lwater. Three grams of glucose, 4 g of Na2HPO4, and 10
mLof the dialysate were then added to the solution outside
the tubing, which was used to grow the bacteria. Bacterial
cells were spun down, and the supernatant was transferred
into a new tube and spun at high speed (10,000 rpm) in a
Beckman JA20 rotor for 20 min to remove remaining cells.
The proteins were then precipitated from the clear super-
natant after the addition of 0.15 V of 50% tri-chloracetic
acid and centrifugation at 10,000 rpm for 20 min. The pre-
cipitated proteins were resuspended in PBL to 1/50 of the
original volume and mixed with an equal volume of 2x
sodium dodecyl sulfate–polyacrylamide gel electrophore-
sis (SDS-PAGE) sample buffer. The pH was readjusted by
blowing ammonia vapor onto the sample until the color
changed from yellow back to blue. After boiling for 2 min,
10 µL was loaded onto a 12% SDS-PAGE and run along a
protein standard (50 ng, 25 ng, 10 ng, and 2 ng of the
appropriate recombinant SAg). 
The proteins were blotted onto a Hybond-c extra nitro-
cellulose membrane (Amersham Life Sciences, Little
Chalfont, UK) by using Western transfer buffer (10%
methanol, 150 mM glycine, 25 mM tris-HCl pH 8.5) and a
Semi-phor semi-dry blotter (Hoefer Scientific Instruments,
San Francisco, CA). The membranes were blocked with
5% milk powder (Anchor, Auckland, New Zealand) in
TBST(120 mM NaCl, 10 mM Tris-HCl ph8, 0.05% Tween
20) for 30 min at room temperature, before incubation with
the appropriate rabbit anti-SAg antiserum (1:5000 in
TBST) overnight at 4°C. The blots were developed by
using the ECL Western Blotting Analysis System
(Amersham Biosciences, Little Chalfont, UK).
Results
Mitogenic Activity in Samples from 
Patients with STSS
Nineteen acute-phase serum samples from patients with
severe invasive streptococcal disease with STSS (n=9) and
without STSS (n=10) were analyzed for mitogenic activi-
ty. Serum samples 96/2 and 99/1 both induced a high pro-
liferative response when tested in a PBL-stimulation assay,
which suggests that they might contain a SAg. Both
patients had bacteremia and STSS. Peritonitis was diag-
nosed in patient 96/2, who recovered after 2 weeks in the
intensive-care unit; TSS was diagnosed in patient 99/1,
who died on the day of admission. 
To identify the SAg responsible for the mitogenic activ-
ity, PBLs were stimulated with serum 96/2 and serum 99/1,
respectively, together with rabbit antibodies against recom-
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Table. Summary of the results from sag genotyping and SAg in vitro expression  
sag gene/SAg protein production 
Serum  Isolate  Focus  spe-a  SPE-A  spe-c  SPE-C  spe-g  SPE-G  spe-h  SPE-H  spe-i  SPE-I  spe-j  SPE-J  smez  SMEZ  ssa  SSA  SMEZ
c 
Focal infection/bacteremia with STSS 
94/31  H292  Fasciitis  -  -  -  -  +  -  +  -  +  ++  +  -  +  -  -  -  + 
95/02  H293  Fasciitis  -  -  -  -  +  -  +  -  -  -  +  -  +  -  -  -  ++ 
96/2  H297  Peritonitis  +  -  -  -  +  ++  -  -  -  -  +  +  +  -  -  -  + 
98/5  H325  Fasciitis  +  +++  -  -  +  -  -  -  -  -  +  -  +  -  +  -  + 
98/8  H327  Cellulitis  -  -  -  -  +  +  -  -  -  -  +  -  +  _  +  +  - 
98/11  H330  Endometritis  +  +++  -  -  +  -  -  -  -  -  +  +  +  -  +  -  + 
99/1  H360  Occult bact.  -  -  +  +  +  +  -  -  -  -  +  -  +  -  -  -  ++ 
99/18  H366  Pneumonia  +  +++  -  -  +  -  -  -  -  -  +  ++  +  -  -  -  + 
20/07  H378  Pneumonia  -  -  -  -  +  -  +  -  -  -  +  -  +  -  +  -  + 
Focal infection/bacteremia, no STSS     
95/8  H295  Cellulitis  -  -  -  -  +  -  -  -  -  -  +  +++  +  -  -  -  ++ 
98/1  H319  Cellulitis  -  -  -  -  +  ++  -  -  -  -  +  ++  +  -  -  -  ++ 
20/01  H369  Pelvic clot  -  -  -  -  +  -  -  -  -  -  +  +  +  -  -  -  +++ 
20/04  H370  Thromobosis  -  -  -  -  +  +  -  -  -  -  +  -  +  -  -  -  - 
Focal infection, no bacteremia, no STSS 
97/15  H307  Bursitis  -  -  +  +++  +  -  -  -  -  -  +  +  +  -  -  -  + 
97/18  H308  Cellulitis  +  -  -  -  +  -  +  -  -  -  +  -  +  -  +  -  - 
97/21  H311  Cellulitis  -  -  -  -  +  -  -  -  -  -  +  -  +  -  -  -  + 
97/23  H314  Cellulitis  +  -  -  -  +  +  +  -  +  -  +  +  +  -  -  -  ++ 
97/24  H315  Cellulitis  +  -  -  -  +  -  -  -  -  -  +  +  +  -  -  -  - 
97/26  H316  Amnionitis  -  -  +  +++  +  +  -  -  -  -  +  ++  +  -  +  -  - 
aSAg, superantigen; SPE, streptococcal pyrogenic exotoxin; SME, streptococcal mitogenic exotoxin; STSS, streptococcal toxic shock syndrome. 
bS. pyogenes isolates from patients with and without STSS were genotyped by polymerase chain reaction with sag specific primers. Concentrated supernatant from the in vitro cultured isolates were 
analyzed for secreted SAgs by using Western blot analysis with recombinant SAg standards. SMEZ expression was also analyzed by using the more sensitive Jurkat cell assay, which has a threshold 
of approximately 10 pg/mL. SAg expression by Western blot: -, no detectable protein; +, <2 ng/mL; ++, 2–10 ng/mL; +++, >10 ng/mL. SMEZ expression by Jurkat assay: -, no detectable SMEZ; +, 
>10 pg/ml (10,000–20,000 cpm); ++, 20,000–30,000 cpm; +++, >30,000 cpm. 
cJurkat assay. 
 binant forms of SPE-A, SPE-C, SPE-G, SPE-J, or SMEZ
(Figure 1A). Addition of anti-SMEZ antibodies resulted in
59% and 68% inhibition of the mitogenic activity of serum
samples 96/2 and 99/1, respectively. Antibodies against
SPE-J inhibited PBLstimulation of serum 96/2 by 51% but
had no substantial effect on the serum 99/1 induced activi-
ty. Anti–SPE-A, anti–SPE-C, and anti–SPE-G antibodies
did not substantially inhibit the activity in both serum sam-
ples, except for a slight inhibition (18%) of serum 96/2
activity by anti–SPE-G antibodies.
The antisera were selective against their individual tar-
get SAg. Anti–SPE-J and anti-SMEZ antiserum were
added to PBLs stimulated with various recombinant SAgs
(SPE-A, SPE-C, SPE-G, SPE-H, SPE-I, SPE-J, SMEZ-1,
SMEZ-2, and SSA), and results showed that anti–SPE-J
antibodies exclusively inhibited the rSPE-J activity,
whereas anti-SMEZ antibodies inhibited the activity of
rSMEZ-1 and rSMEZ-2 (Figure 1B). To quantify the lev-
els of SAg in 96/2 and 99/1 serum samples, a comparison
was made against a standard PBL proliferation response
for recombinant SMEZ-1 and rSPE-J. Five percent of each
serum resulted in 33,000–34,000 cpm after 3[H]-thymidine
uptake, which is equivalent to 1–10 pg/mL of rSMEZ-1 or
rSPE-J (Figure 2). The 99/1 activity was titratable and still
detectable at 0.05% serum. Insufficient 96/2 serum pre-
vented a similar dilution assay.
STSS Patient 96/2 and Seroconversion to SMEZ
Sequential serum samples from STSS patient 96/2 up
to day 9 after admission to hospital were analyzed for
clearance of mitogenic activity. Figure 3 shows that the
highest mitogenic activity occurred 1.5 days postadmis-
sion (serum 96/2-2). At day 2 postadmission, an 80%
reduction of activity had occurred, and by day 3 after
admission SAg activity was undetectable. Patient 99/1
died on the day of admission, which prevented sequential
serum analysis. 
The sequential serum samples from patient 96/2
allowed us to analyze for the development of neutralizing
anti-SAg antibodies by using patient serum to inhibit the
activity of recombinant SAgs in a PBL-stimulation assay
(Figure 4). On day 3, patient 96/2 had neutralizing antibod-
ies against SPE-A, SPE-C, SPE-I, and SSA but unde-
tectable levels of protective antibodies against SMEZ-1,
SMEZ-2, SPE-G, and SPE-H. By day 9 after admission
(sample 96/2-10), the serum contained high titers of neu-
tralizing antibodies against SPE-A, SPE-C, SPE-I, SSA,
SMEZ-1, and SMEZ-2, and a moderate anti–SPE-H titer.
No antibodies against SPE-G were detected. These results
show seroconversion for SMEZ-1 and SMEZ-2 antibodies
in the STSS patient 96/2, adding further evidence that
SMEZ was the predominant SAg causing STSS in this
patient. 
Addition of serum 96/2-4 or 96/2-10 selectively
increased the mitogenicity of SPE-J by twofold compared
to the FCS control. This selective increase suggests that the
serum might contain a substance that selectively syner-
gizes SPE-J activity, which prevented any evaluation of
the anti–SPE-J antibody titer in the two sequential serum
samples. 
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Figure 1. Inhibition of mitogenic activity in sera 96/2 and 99/1 with
anti-superantigen (SAg) antisera. A) Peripheral blood lymphocytes
(PBLs) were stimulated with 5% patient serum in the presence of
5% anti-SAg antiserum or 5% fetal calf serum (FCS) only. After 3
days, 3[H]-thymidine was added, and PBLs were incubated for
another 24 h, before being washed and counted. The results were
blotted as percentage of inhibition with specific anti-SAg serum
compared to FCS. Antistreptococcal pyrogenic exotoxin (SPE)-J
antiserum inhibited the mitogenic activity of serum 96/2 by 51%,
while antistreptococcal mitogenic exotoxin (SME) Z antiserum
inhibited the activity in 96/2 by 59% and the serum in 99/1 by 68%.
B) The specificities of the anti–SPE-J and anti–SMEZ sera were
demonstrated by stimulating PBLs with recombinant SAgs in the
presence of 5% antiserum. SSA, streptococcal superantigen.Serum 96/2-10 (9 days after admission) was analyzed
for protective antibodies against SMEZ-1, -2, -3, -4, -5, -7,
-8, -9, -13, -16, -20, -21, and -22 and found to neutralize
the activity of all tested SMEZ variants (data not shown).
Inhibition of approximately 95% was seen with all SMEZ
variants, except SMEZ-2 (88%), SMEZ-16 (78%), and
SMEZ-22 (85%), indicating that challenge with a single
SMEZ variant resulted in a cross-reactive antibody
response against all SMEZ variants. 
Matching GAS isolates from all 19 patients were geno-
typed for sag genes. The frequencies were 100% (smez,
speG, speJ), 36.8% (speA), 31.6% (ssa), 26.3% (speH),
15.8% (spC), and 10.5% (speI) (Table). We observed no
difference in sag gene frequencies between patients with
STTS and patients without STSS. The smez alleles of both
GAS strains isolated from patients 96/2 and 99/1 were ana-
lyzed by DNAsequencing and identified as smez-1 (H297)
and smez-16 (H360). 
All GAS isolates were grown in liquid culture, and the
supernatants were analyzed for secreted SAgs by Western
blot using rabbit antisera against individual recombinant
SAgs (Table). The selectivity of each antiserum was tested
with the complete panel of recombinant SAgs in Western
blots, and no cross-reactivity was observed (data not
shown). SPE-Awas expressed in substantial amounts only
from isolates from patients with STSS (isolates H325,
H330, and H366). Isolates from patients without STSS that
carry the speA gene (H308, H314, and H315) had unde-
tectable levels of SPE-A. However, patients infected with
the SPE-A–producing strains did not show any mitogenic
activity in their acute-phase serum samples. In contrast,
GAS isolated from the patients 96/2 and 99/1 (H297 and
H360) produced only small amounts of SMEZ in vitro
despite the relatively large amounts detected in the acute-
phase serum samples. In vitro–produced SMEZ could not
be detected in Western blots, indicating a concentration of
<1 ng/mL, and could only be detected using the more sen-
sitive Jurkat cell proliferation assay that has a lower sensi-
tivity threshold (approximately 10 pg/mL). 
Discussion
Over the last 2 decades, a large increase in GAS-medi-
ated severe invasive disease has occurred (5,24,25).
Streptococcal SAgs have been implicated in STSS and
other severe streptococcal infections. Evidence for SAg
involvement in these diseases derived from studies show-
ing higher frequencies of speA and speC genes in severe
disease isolates compared to nonsevere disease isolates
(2,22–25), and reports of strong proliferative responses in
the acute-phase serum samples from a patient with STSS
(28) and from mice infected with a SAg-producing S. pyo-
genes strain (29). 
In this study, we analyzed 19 acute-phase serum sam-
ples from patients with severe streptococcal disease with
STSS (n=9) and without STSS (n=10) for mitogenic activ-
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Figure 2. Mitogenic activity of acute-phase serum samples 96/2
and 99/1 compared to recombinant superantigens (SAgs).
Peripheral blood lymphocytes were stimulated for 4 d with various
dilutions of recombinant SAg or acute-phase serum sample 99/1.
No dilution was carried out for 96/2 because of limited amount of
serum. Five percent of each of the patient serum samples showed
a proliferative response equal to 1–10 pg/mL of recombinant strep-
tococcal pyrogenic exotoxin J or recombinant streptococcal mito-
genic exotoxin 1. Serum 99/1 still showed significant mitogenic
activity at 0.05%. SME, streptococcal mitogenic exotoxin; SPE,
streptococcal pyrogenic exotoxin.
Figure 3. Clearance of the mitogenic activity in sequential sera
from patient 96/2. Peripheral blood lymphocytes were stimulated
with 5% of acute-phase and sequential serum samples from
patient 96/2. The mitogenic activity reached the highest point on
day 1.5 after admission to hospital and dropped sharply on day 2.
No substantial activity was found in sequential serum samples
from day 3 on (samples 96/2–4 to 96/2–10). FCS, fetal calf serum.ity and detected SMEZ in samples from 2 STSS patients
(96/2 and 99/1). One of the serum samples (96/2) also con-
tained detectable amounts of SPE-J. 
The mitogenic activity in the two serum samples was
equivalent to 1–10 pg/mL and 10 pg/mL of SMEZ-1 or
SPE-J, which is sufficient to trigger maximal T-cell activa-
tion in PBL-stimulation assays. However, this concentra-
tion remains an estimate as inhibitory effects of serum
components were not defined. 
The sequential serum of the surviving patient (96/2)
showed no protective anti-SMEZ antibodies on day 3 after
admission (serum 96/2–4) but substantial levels at day 9
(serum 96/2–10), which suggests a direct role of this toxin
in the STSS of this patient. Challenge with SMEZ-1 (the
SMEZ variant produced by GAS isolate H297 from patient
96/2) resulted in a broad neutralization response against
the complete range of SMEZ variants. We have shown pre-
viously that some variation in healthy blood donors exists
in neutralizing antibodies to SMEZ variants because of
antigenic variation (33). Whether broad-spectrum anti-
SMEZ responses are a result of a few cross-reacting anti-
bodies that were raised against a single SMEZ variant has
yet to be established, as does whether it results from infec-
tion by multiple GAS strains carrying different smez al-
leles over a certain period. Our results indicate the produc-
tion of cross-reactive SMEZ antibodies in patient 96/2.
However, this response might not reflect a general
response, and SMEZ concentration in the blood might play
a critical role.
Analysis of the 19 matching GAS isolates showed no
bias in sag genotype between STSS isolates and non-STSS
isolates. Furthermore, the results are consistent with the
sag gene frequencies previously observed in 39 S. pyo-
genes isolates from New Zealand patients with sore throat
(n=29), wound infection (n=4), acute glomerulonephritis
(n=1), otitis (n=1), endometritis (n=2), rheumatic fever
(n=1), and skin ulcer (n=1) (36). The only substantial dif-
ference was the frequency of the speC gene, found in 42%
of New Zealand isolates and 15.8% of London isolates.
These results suggest that genotyping of sag genes alone is
not predictive for type or severity of streptococcal disease. 
We found no substantial difference in SAg production
in cell cultures between STSS and non-STSS strains, with
the exception of SPE-A, which was only expressed in
STSS strains and suggests a tight association of SPE-A in
some cases of STSS. These data are consistent with data
from other groups that showed a link between SPE-A
expression and severe streptococcal disease (17,22,23).
Evidence points to very different regulation of SAg pro-
duction between in vitro culture and in vivo infection.
SMEZ-1, for example, was undetectable in cultures of iso-
late H297 except by the sensitive Jurkat proliferation
assay, yet the patient with this GAS isolate had high serum
levels of SMEZ-1, indicating that SMEZ production is
tightly regulated. Kazmi et al. showed the in vivo induc-
tion of the speA gene by using a micropore Teflon diffu-
sion chamber implanted subcutaneously in BALB/c mice
(37). Broudy et al. observed an induction of SPE-C after
they co-cultured a speC-carrying isolate with a human pha-
ryngeal cell line (35). Some, if not all, SAgs can likely be
induced or upregulated by an unknown host factor. 
Despite the fact that SMEZ is poorly expressed in vitro
while most other SAgs are frequently produced in culture,
SMEZ appears to be the predominant bioactive circulating
SAg at the time of admission. This observation is in keep-
ing with recent findings using isogenic smez+ and smez-
bacteria in a mouse model (29).
We attempted to correlate streptococcal disease and dis-
ease severity with the production of a particular SAg.
Although the patient cohort is small, no direct correlation
between disease severity and sag genotype/SAg produc-
tion is evident; other factors likely contribute to STSS
severity. Importantly, host factors may enhance the pro-
duction of particular SAgs and, in addition, the immuno-
genic background of the host may contribute to the sever-
ity of SAg-mediated invasive streptococcal disease, as
recently reported (38). Although the overall potential role
of SAgs in severe streptococcal disease remains elusive,
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Figure 4. Seroconversion of patient 96/2 against streptococcal
superantigens (SAgs). Peripheral blood lymphocytes were stimu-
lated with various recombinant streptococcal SAgs in the presence
of serum 96/2–4, 96/2–10, or fetal calf serum only. The columns
show the percentage of inhibition of recombinant SAgs by neutral-
izing antibodies in patient serum samples. The sequential serum
on day 3 showed a complete lack of neutralizing antistreptococcal
mitogenic exotoxin (SME) Z antibodies, while serum 96/2–10 con-
verted to a high anti-SMEZ antibody titer. Both sera enhanced the
mitogenic activity of recombinant streptococcal pyrogenic exotox-
in J, which suggests the presence of an unknown synergistic fac-
tor. SPE, streptococcal pyrogenic exotoxin; SSA, streptococcal
superantigen.our results directly implicate SMEZ in the onset of STSS
in at least two patients. This presence of a particular biore-
active SAg in the blood of patients with a reemerging
potentially fatal disease is new and provides a platform for
further investigation of the role of this potent SAg in dis-
ease pathophysiology.
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